Active, not recruitingPhase 2

Ketamine for Methamphetamine Use Disorder

NCT06496750 · KMD · University of Texas Southwestern Medical Center

Closed to entry

Status

Not accepting participants

Phase 2

Phase

120

Target enrolment

Study sites

5 US states

What it is testing

Summary

This study aims to determine whether treatment response with IV ketamine is superior to treatment response with IV midazolam in adults with moderate to severe MUD. The study design is a 12-week randomized, double-blind, controlled trial comparing intravenous (IV) ketamine against IV midazolam, delivered over six weeks in 120 adults with moderate to severe methamphetamine use disorder (MUD).

Summary as written by the trial’s own sponsor and published on ClinicalTrials.gov API v2. It is the sponsor’s description, reproduced unedited, not an assessment by this site.

What counts as success

Primary outcome measures

Treatment Response
Measured over 2 weeks

A trial succeeds or fails on its primary outcome, declared in advance. Everything else it reports is secondary by definition.

Who can take part

Eligibility, as published

18 Years to 65 Years

Ages

All

Sex

Not accepted

Healthy volunteers

Inclusion criteria Study participants must: 1. Be 18 to 65 years old 2. Be able to sufficiently understand, speak, and read English 3. Be interested in reducing or stopping methamphetamine use 4. Meet criteria for methamphetamine use disorder 5. Use acceptable methods of contraception during participation in the study Exclusion criteria Study participants must not: 1. Have been in a research study of pharmacological or behavioral treatment for addiction within 6 months prior to written informed consent 2. Be currently in jail, prison, or inpatient overnight facility as required by court of law 3. Have upcoming surgery planned or scheduled 4. Be currently pregnant, breastfeeding, or planning on conception, if biologically female Additional inclusion and exclusion criteria will be assessed by the study investigators at the screening visit.

Where

5 study sites

Facility	City	Region	Country
Alameda Health System	San Leandro	California	United States
Interdisciplinary Substance Use and Brain Injury Facility	Albuquerque	New Mexico	United States
Addiction Institute of Mount Sinai	New York	New York	United States
Prisma Health	Greenville	South Carolina	United States
UT Southwestern Medical Center	Dallas	Texas	United States

On the registry

Contact the trial directly

This site does not enrol anyone and is not involved in this trial. To ask about taking part, use the sponsor’s own contact details on the official registry record, which is also where the most current version of everything above lives.

Before you do, the preparation checklist lists what a site will ask you on a first call and what is worth asking them. It is free and collects nothing.

NCT06496750 on ClinicalTrials.gov →

Last updated in the registry 2026-08-11. Registry records change; this page reflects the data build of 2026-08-25.

Where this trial sits

Substance

Ketamine

Indication

Recruiting in

All 3 trials from University of Texas Southwestern Medical Center →